Miller Industries at 17th Annual Midwest IDEAS Conference: growth bets

Miller Industries (MLR) reported Q2 revenue of $240M and diluted EPS of $0.63, while returning $4.9M to shareholders via dividends and buybacks. The company reaffirmed FY2026 guidance of $850M–$900M revenue with EPS in line with 2025 and mid-13% gross margins, alongside a capacity expansion plan totaling $100M in Tennessee and €8M in France. After normalizing a 2025 inventory issue (inventory back to ~7-year averages by Q1 2026) and paying down its revolver to $0, shares are up 54% YTD, though an indicated overvaluation vs fair value suggests the rally may already price in much of the military-driven growth (>$200M in commitments; production late-2027; revenue mostly 2028–2029).

Analysis

The market is likely overpaying for a story that is still mostly two years away from cash conversion. Near-term earnings power looks capped by flat end-demand and channel normalization, while the valuation is already reflecting an eventual step-up in military mix that won’t show up in reported P&L until late 2027 at the earliest. That creates a classic timing mismatch: the stock can keep outperforming on narrative, but fundamentals need several quarters of boring execution to justify the multiple.

The real winner here may be the distributor network, not the equity holders at current prices. Normalized inventory and zero revolver debt reduce near-term balance-sheet risk, but they also remove the one source of operating leverage that could surprise to the upside in 2026; if the channel is already clean, incremental upside must come from order acceleration that management itself says it does not currently see. Second-order, this argues for caution on suppliers tied to chassis and working capital financing, since any re-accumulation would pressure terms and delay cash conversion.

Contrarian view: the moat is probably real, but the market may be underestimating how much of the apparent military option is already capitalized. Because the expansion is funded largely from cash flow and the revenue lift is delayed, the thesis is vulnerable to a simple falsifier: if 2H26 bookings stay flat and the stock cannot hold above recent highs despite no guidance raises, the premium should compress. The upside case requires visible backlog conversion or a meaningful 2027 pre-build signal; absent that, this is more of a watchlist name than a chase.

For broader second-order effects, this is modestly constructive for specialty industrial automation/capex spend and not a meaningful read-through for AMZN or NVDA despite the tech-led tape. Any benefit to CPRT is indirect at best and would come only from higher accident-driven replacement activity, which is not the core driver here. The cleaner trade is against valuation and timing, not against the business model itself.

Key Decisions for Investors

• Fade strength in MLR on rallies above the 52-week high: initiate a tactical short or buy 1-3 month put spreads if the stock holds near peak levels without an upward revision to 2026 revenue/EPS. Risk/reward is attractive because the next major fundamental inflection is not until late 2027, while the multiple is already elevated.
• Set a watch trigger on MLR 2H26 orders/backlog: if management does not convert the current military commitment stack into visible build-rate acceleration by the next two quarters, expect multiple compression. Falsifier for the bearish view is a meaningful guidance raise or a new large contract announcement.
• Prefer patience over chasing the long: if taking exposure, use call spreads only after evidence that 2027 pre-build spending is pulling forward revenue, not just expanding capacity. A better entry would be after a post-conference pullback of 10-15% from current levels.
• Relative-value idea: long CPRT / short MLR as a valuation-vs-execution pair only if salvage-volume indicators reaccelerate. This is a weak pair, but it captures the idea that CPRT has a more immediate operating linkage to incident frequency and fleet turnover, while MLR’s upside is deferred.
• Avoid extrapolating the headline into broader industrial beta: no action on AMZN, NVDA, or CVX from this name alone. Treat MLR as a single-name valuation/timing trade, not a sector call.